Fresenius' profits surpass expectations, with sales projections on the rise
Fresenius posts impressive Q2 2025 earnings with revenue of €5.57 billion, marking a 5% organic growth compared to the previous year[1][2][4]. The company's Group EBIT remained relatively stable at €654 million, with an underlying EBIT margin of 11.7%. Net income grew by 8% to €412 million in constant currency, and EPS followed suit, rising by 8% to €0.73[1][2].
Notably, Fresenius has revised its revenue forecast for the current year, anticipating a growth of 5-7%, up from the previous target of 4-6%[1][2][4]. This positive outlook is largely due to the strong performance of Fresenius Kabi and Fresenius Helios.
Key highlights: - Group revenue: €5,571 million (+5% organic growth) - Group EBIT: €654 million, margin 11.7% - Net income: €412 million (+8% in constant currency) - EPS: €0.73 (+8% in constant currency) - Net debt/EBITDA ratio: 3.1x
In a move to maintain its stake in Fresenius Medical Care (FMC), Fresenius has taken measures including a pro rata sale of FMC shares during FMC's share buyback program[1][2]. Despite the share buyback program, Fresenius plans to continue its ownership in FMC.
Fresenius Medical Care has also announced a share buyback program. However, potential new investors are cautiously waiting for positive chart signals before making a purchase[1][2].
The current price stop for buying Fresenius's stock stands at €35.00[1]. DER AKTIONÄR remains confident in the medium to long-term investment story of Fresenius[1].
[1] - Source: Fresenius Q2 2025 Earnings Release [2] - Source: Fresenius Q2 2025 Earnings Conference Call [4] - Source: Fresenius Q2 2025 Earnings Presentation
The impressive Q2 2025 earnings report of Fresenius indicates a 5% organic growth in finance, demonstrating a strong business performance. Looking ahead, Fresenius has raised its revenue forecast for the current year, expecting a growth of 5-7%, potentially increasing investment opportunities in the finance and business sectors.
